PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Stockholders in Incline Village, Nevada. At the annual meeting,
the Companys stockholders: (i) elected each of David Gryska and
Paul Sandman to the Companys Board of Directors for a term of
three years, (ii) ratified the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December 31,
2017, (iii) approved, on an advisory basis, the compensation of
the Companys named executive officers as disclosed in the
Companys proxy statement and (iv) indicated, on an advisory
basis, that every year is the preferred frequency for stockholder
advisory votes on the compensation of the Companys named
executive officers.
130,238,633 shares of the Companys common stock, or 80.51% of the
total number of shares outstanding as of the record date. The
results of the matters submitted to a stockholder vote at the
annual meeting were as follows.
|
Name
|
For
|
Withheld
|
Broker Non-Votes
|
|||
|
David Gryska
|
91,324,115
|
2,893,462
|
36,021,056
|
|||
|
Paul Sandman
|
91,398,485
|
2,819,092
|
36,021,056
|
|
2.
|
Ratify the appointment of PricewaterhouseCoopers LLP as the
independent registered public accounting firm for the fiscal year ending December 31, 2017: |
|
For
|
Against
|
Abstain
|
|
128,384,271
|
1,352,115
|
502,247
|
|
3.
|
Approve, on an advisory basis, the compensation of the
Companys named executive officers as disclosed in the Companys proxy statement: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
|
89,529,375
|
4,243,979
|
444,223
|
36,021,056
|
|
4.
|
Indicate, on an advisory basis, the preferred frequency of
stockholder advisory votes on the compensation of the Companys named executive officers: |
|
Every Year
|
Every 2 Years
|
Every 3 Years
|
Abstain
|
Broker Non-Votes
|
|
81,626,699
|
476,558
|
11,693,831
|
420,489
|
36,021,056
|
About PDL BioPharma, Inc. (NASDAQ:PDLI)
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.
